ArticleClinical pharmacology and therapeutics2026
Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer.
Vaishali L Chudasama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.